Clinical trials: Antipsychotic Induced Weight Gain
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
High Risk MC4R Genotype, Low Risk MC4R Genotype
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old.
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Trial name
- NCT01844700
- Testing
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwell Health